Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Aldeyra Therapeutics stock

Own Aldeyra Therapeutics stock in just a few minutes.

Aldeyra Therapeutics, Inc is a biotechnology business based in the US. Aldeyra Therapeutics shares (ALDX) are listed on the NASDAQ and all prices are listed in US Dollars. Aldeyra Therapeutics employs 11 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Aldeyra Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ALDX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Aldeyra Therapeutics share price

Use our graph to track the performance of ALDX stocks over time.

Aldeyra Therapeutics shares at a glance

Information last updated 2021-04-28.
52-week range$2.60 - $14.62
50-day moving average $11.76
200-day moving average $9.67
Wall St. target price$25.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.00

Buy Aldeyra Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Aldeyra Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aldeyra Therapeutics financials

Gross profit TTM $0
Return on assets TTM -27.28%
Return on equity TTM -69.81%
Profit margin 0%
Book value $1.54
Market capitalisation $662.3 million

TTM: trailing 12 months

Shorting Aldeyra Therapeutics shares

There are currently 4.7 million Aldeyra Therapeutics shares held short by investors – that's known as Aldeyra Therapeutics's "short interest". This figure is 2.3% down from 4.8 million last month.

There are a few different ways that this level of interest in shorting Aldeyra Therapeutics shares can be evaluated.

Aldeyra Therapeutics's "short interest ratio" (SIR)

Aldeyra Therapeutics's "short interest ratio" (SIR) is the quantity of Aldeyra Therapeutics shares currently shorted divided by the average quantity of Aldeyra Therapeutics shares traded daily (recently around 767224.9589491). Aldeyra Therapeutics's SIR currently stands at 6.09. In other words for every 100,000 Aldeyra Therapeutics shares traded daily on the market, roughly 6090 shares are currently held short.

However Aldeyra Therapeutics's short interest can also be evaluated against the total number of Aldeyra Therapeutics shares, or, against the total number of tradable Aldeyra Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aldeyra Therapeutics's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Aldeyra Therapeutics shares in existence, roughly 100 shares are currently held short) or 0.1229% of the tradable shares (for every 100,000 tradable Aldeyra Therapeutics shares, roughly 123 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Aldeyra Therapeutics.

Find out more about how you can short Aldeyra Therapeutics stock.

Aldeyra Therapeutics share dividends

We're not expecting Aldeyra Therapeutics to pay a dividend over the next 12 months.

Aldeyra Therapeutics share price volatility

Over the last 12 months, Aldeyra Therapeutics's shares have ranged in value from as little as $2.6 up to $14.6178. A popular way to gauge a stock's volatility is its "beta".

ALDX.US volatility(beta: 1.72)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aldeyra Therapeutics's is 1.7242. This would suggest that Aldeyra Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Aldeyra Therapeutics overview

Aldeyra Therapeutics, Inc. , a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of primary vitreoretinal lymphoma. The company's portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative diseases and covid-19; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, allergy, and covid-19, as well as ADX-103 for the treatment of retinal diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site